Search

Contributor:

Jennifer Lim, MD

PANORAMA 100-Week Data: Updates From ARVO 2020

Reconsidering treatment endpoints in real-world clinical practice: is achieving a favorable retreatment interval a goal of therapy?

PANORAMA 100-Week Data: Updates From ARVO 2020

Jennifer Lim, MD

100-Week Data vs. 52-Week Data in PANORAMA

100-Week Data vs. 52-Week Data in PANORAMA

Jennifer I. Lim, MD

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Maria Berrocal, MD and Jennifer Lim, MD

What's New in Wet AMD: Phase 3 Updates

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

Women in Retina

Women in Retina

Anne E. Fung, MD, Jennifer I. Lim, MD, Nancy M. Holekamp, MD

Pneumatic Retinopexy

Pneumatic Retinopexy

Jennifer I. Lim, MD

Recurrent PVR

Recurrent PVR

Jennifer I. Lim, MD

Subretinal PFO with Air

Subretinal PFO with Air

Jennifer I. Lim, MD

Epithelial Downgrowth Managment with Vitrectomy

Epithelial Downgrowth Managment with Vitrectomy

Jennifer I. Lim, MD

K-Pro Combo Surgery

K-Pro Combo Surgery

Kyle D. Kovacs, MD, and Jennifer I. Lim, MD

Efficacy of Faricimab with PEDs Revealed

Efficacy of Faricimab with PEDs Revealed

Jennifer I. Lim, MD

Surgical Pearls for Sickle Cell Retinopathy

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

ASRS Meeting Coverage Day 3: DR Biomarkers and Gene Tx for Achromatopsia

Jennifer Lim, MD; and Lejla Vajzovic, MD

Reconsidering treatment endpoints in real-world clinical practice: is achieving a favorable retreatment interval a goal of therapy?

Carl D. Regillo, MD; Jennifer Lim, MD; and Charles Wykoff, MD, PhD

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Diana Do, MD; and Jennifer Lim, MD